Requests for treatment with daraxonrasib must come from licensed U.S. physicians ...
FDA granted rapid expanded access for daraxonrasib in previously treated metastatic PDAC, reflecting urgency and a ...
The EAP is designed to provide eligible patients access to leronlimab outside of a clinical study setting. The program is intended for patients who have exhausted available treatment options and are ...